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Abstract 
Background: The cost-effectiveness of screening for type 2 diabetes mellitus (DM2) in developing countries remains 
unknown. The Brazilian government conducted a nationwide population screening program for type 2 diabetes 
mellitus (BNDSP) in which 22 million capillary glucose tests were performed in individuals aged 40 years and older. 
The objective of this study was to evaluate the life-time cost-effectiveness of a national population-based screening 
program for DM2 conducted in Brazil.
Methods: We used a Markov-based cost-effectiveness model to simulate the long-term costs and benefits of 
screening for DM2, compared to no screening program. The analysis was conducted from a public health care system 
perspective. Sensitivity analyses were conducted to examine the robustness of results to key model parameters.
Results: Brazilian National diabetes screening program will yield a large health benefit and higher costs. Compared 
with no screening, screen detection of undiagnosed diabetes resulted in US$ 31,147 per QALY gained. Results from 
sensitivity analyses found that screening targeted at hypertensive individuals would cost US$ 22,695/QALY. When 
benefits from early glycemic control on cardiovascular outcomes were considered, the cost per QALY gained would 
reduce significantly.
Conclusions: In the base case analysis, not considering the intangible benefit of transferring diabetes management 
to primary care nor the benefit of using statin to treat eligible diabetic patients, CE ratios were not cost-effective con-
sidering thresholds proposed by the World Health Organization. However, significant uncertainty was demonstrated 
in sensitivity analysis. Our results indicate that policy-makers should carefully balance the benefit and cost of the 
program while considering using a population-based approach to screen for diabetes.
© 2015 Toscano et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The socioeconomic burden of type 2 diabetes mellitus 
(DM2) is large and increasing. Early detection and treat-
ment of DM2 seems a logical preventive action for sev-
eral reasons. First, diabetes-related complications can 
occur before diabetes clinical diagnosis. Second, effi-
cacy of early treatments in reducing complications is 
well established [1–8]. Third, acceptable and accurate 
screening tests are available [9, 10]. Importantly, recent 
evidence failed to demonstrate significant impact of 
screening asymptomatic individuals at increased risk 
for diabetes in reducing all-cause, cardiovascular, or dia-
betes-related mortality within 10 years [11]. However, a 
number of institutions have recommended opportunis-
tic screening for high-risk individuals in certain circum-
stances [12–16]. Opportunistic screening, carried out at 
a time when people are seen, by healthcare professionals, 
for a reason other than the disorder in question, is one of 
the potential approaches to screening for DM2 [12].
Several countries have implemented opportunistic 
selective DM2 screening in high-risk populations [12]. By 
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contrast, Brazil has implemented a massive population-
based diabetes screening program.
The prevalence of diabetes in Brazil is high and rep-
resents one of the major challenges to the Brazilian 
publicly-funded National Healthcare System (SUS) [17]. 
In 2001, the Brazilian Ministry of Health implemented 
a public health strategy aiming at reorganizing diabe-
tes and hypertension care delivery. The main aim of 
this strategy was to shift the focus of diabetes care from 
hospitals to primary care settings. A cornerstone of the 
strategy was the Brazil Nationwide Diabetes Screening 
Program (BNDSP), a one-time screening program con-
ducted through primary healthcare services using finger-
stick capillary blood glucose testing. Over 13,000 health 
care providers in approximately 40,000 SUS primary 
health care centers among Brazil’s 5507 municipalities 
were trained in diabetes diagnosis and management [18]. 
The BNDSP targeted 31 million adults aged 40 years or 
older who received health care through the SUS. Capil-
lary blood glucose testing was conducted. With a mas-
sive participation rate, between March 6 and April 7, 
2001, 22.1 million capillary blood glucose tests were per-
formed. An initial assessment found that the program led 
to the diagnosis of approximately 345,000 new cases of 
diabetes at a cost of US$ 76 per case [19].
Determining whether to incorporate such a public 
health strategy into standard practice requires weigh-
ing the estimated benefits of population screening in 
reducing long-term complications against the long-term 
costs it generates. Following global recommendations 
for countries conducting screening strategies [12], the 
objective of this study is to evaluate the long-term cost-
effectiveness of the BNDSP. Specifically, we estimated the 
lifetime costs and benefits of universal screening for type 
2 diabetes compared to standard practice in Brazil, that 
is, no organized screening, taking the perspective of the 
Brazilian Public Healthcare System.
Methods
We conducted a cost-effectiveness study in which a vali-
dated Markov model was populated with data from a 
national population-based screening program for DM2 
conducted in Brazil, to evaluate the life-time costs and 
benefits of screening for DM2.
Screening
During the BNDSP, a positive screening test was defined 
by a fasting capillary glucose ≥100 mg/dL or a casual glu-
cose ≥140 mg/dL, and fasting was defined as absence of 
food ingestion for at least 4  h prior to capillary glucose 
test [18]. Sensitivity and specificity of capillary blood 
glucose screening considered in the model were 68 and 
89  %, respectively [10]. These values were estimated 
considering the BNDSP participants reporting to be in 
fasting condition (47  %), for which the cut-off for posi-
tive test results was 100  mg/dL, and non-fasting condi-
tion (53 %), for which the cut-off was 140 mg/dL [19]. An 
additional fasting plasma glucose test and two extra phy-
sician visits were required for diagnostic confirmation of 
diabetes.
Universal DM2 screening as conducted in the BNDSP 
was compared to standard practice in Brazil at that time, 
that is, no organized screening. Progression of individu-
als with and without diabetes in the screening module is 
represented in Fig. 1. Individuals diagnosed with diabetes 
were assumed to enter the diabetes disease progression 
model (Fig. 2), described below.
Post‑screening interventions considered
During the BNDSP, specific recommendations were 
given regarding treatment. Diagnosed cases were man-
aged aiming at blood pressure target of 135/80  mmHg 
and fasting serum glucose level of 110 mg/dL. Therefore, 
we assumed that intensified glycemic and hypertension 
treatment were promptly initiated at diagnosis. Based 
on the United Kingdom Prospective Diabetes Study 
(UKPDS), we assumed the intensified glycemic control 
consisted of one or more generic drugs (metformin, glib-
enclamide, and/or insulin) aiming at fasting serum glu-
cose level of 110 mg/dL [1, 20]. The effect of intensified 
glycemic treatment is modeled as slowing progression 
of microvascular complications by reducing hemoglobin 
A1c, and thus lowering hazard rates for microalbuminu-
ria, nephropathy, peripheral neuropathy, and photoco-
agulation [1]. No effects on macrovascular complications 
were assumed in the base case [1].
All persons with hypertension were assumed to receive 
standard hypertension treatment (targeting diastolic 
blood pressure of 90  mmHg) until they receive a diag-
nosis of diabetes, after which they receive intensified 
hypertension treatment (targeting diastolic blood pres-
sure of 85 mmHg) [3] consisting of angiotensin convert-
ing enzyme inhibitor (captopril), β blocker (propranolol) 
or thiazides as single or combination therapy [2]. Model 
estimates of this approach assumed a 17–44  % relative 
risk reduction for stroke and 13  % risk reduction for 
CHD [2].
Model
We used a modified version of the CDC/RTI type 2 dia-
betes cost-effectiveness simulation model to simulate 
the long-term health and economic consequences of the 
BNDSP. The CDC/RTI model is a Markov-based model 
developed by the Centers for Disease Control and Pre-
vention and RTI International (CDC/RTI). The model 
simulates disease progression based on annual transition 
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of multiple disease states. The outcomes include lifetime 
development of diabetic complications, diabetes-related 
health care costs, life years, and quality adjusted life years 
gained (QALYs) [21]. In progressing through the model 
from the onset of diabetes to death, people with diabe-
tes can develop five types of complications: nephropathy, 
neuropathy, retinopathy, coronary heart disease (CHD), 
and stroke (Fig. 2). Each complication/health state has a 
corresponding health utility value ranging from 0 (death) 
to 1 (perfect health). The basic model structure and 
key model parameters have been previously described 
[21–23]. Annual transition probabilities for the health 
states considered in the model are presented in Table 1.
The model includes a screening module, and assumes 
that in the absence of screening, diagnosis would occur 
10 years after its onset while screening would reduce this 
pre-diagnosis interval by 5 years [24]. Progression of per-
sons through screening and clinical diagnosis is shown in 
Fig. 2.
The CDC/RTI model has been used to assess the cost-
effectiveness of screening for undiagnosed type 2 diabe-
tes and pre-diabetes in the United States [22, 23]. For this 
Fig. 1 Progression of individuals in the screening module, Nationwide Population Screening Program for Diabetes. Brazil, 2001
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study, we adjusted epidemiological and cost parameters 
using Brazilian data.
Epidemiological data
Demographic and mortality data for the general pop-
ulation were obtained from the Brazilian National 
Institute for Geography and Statistics (IBGE) for 
2002. Prevalence of risk factors for cardiovascular 
complications in the Brazilian population was based 
on surveys [25–27] (Table 2). Estimates of undiagnosed 
diabetes prevalence by age-groups and hypertension 
level were obtained from the BNDSP [28] (Table  2). 
Age and gender-specific estimates of the incidence of 
true diabetes in the population were obtained apply-
ing DISMOD II software [29] to data from a prevalence 
survey [30].
Fig. 2 Markov model of diabetes disease progression
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Economic data
Four types of costs were considered: associated with 
diabetes screening, diabetes treatment, diabetes-related 
complications, and other medical care.
Costs associated with screening and confirmatory diag-
nosis have been previously estimated based on actual 
expenses of the BNDSP, which has been previously 
described [19]. A total of 22.1 million capillary glucose 
tests were performed, of which 16.4  % were positive. 
Total screening and diagnostic costs were US$ 26.19 mil-
lion (Int$ 104.32 million), including national level costs 
of diagnostic material, social mobilization and media 
campaign, training of healthcare workers, and manage-
ment costs. The screening cost per screened individual 
was estimated at US$ 1.16. Diagnostic confirmation costs 
were US$ 2.97 per each individual screened positive dur-
ing the BNDSP.
The costs of glycemic control included three resource 
components: drug use, physician visits, and self-testing 
[31]. Treatment modalities considered were oral hypo-
glycemic agents only, insulin only, and both oral hypo-
glycemic agents and insulin. Intensified glycemic control 
considered initial treatment with metformin. The pro-
portion using each drug regimen varied by duration of 
diagnosed diabetes and was estimated from the UKPDS 
[1, 32]. Daily cost of medications were estimated consid-
ering average market prices assuming standard doses. 
Incremental cost of intensive glycemic control (relative to 
standard control) was estimated per year, depending on 
the number of years since diagnosis.
The costs of standard and intensified hypertension 
control were estimated to reflect clinical practice in 
Brazil, where standardized drug regimens include the 
use of generic thiazides, propranolol, and captopril. We 
assumed that the maximum number of drugs that would 
be taken at any given time was three [33]. The incre-
mental cost of intensive hypertension control, relative to 
standard control, was estimated per year, depending on 
the number of years since diabetes diagnosis.
Cost of diabetes-related complications included the 
cost of nephropathy, neuropathy, retinopathy, CHD, 
and stroke. One-time and annual costs of complica-
tions considered in the model (Table 3) were calculated. 
Healthcare resource utilization was estimated based on 
Brazilian guidelines, considering diagnosis and annual 
follow-up procedures for end stage renal disease, angina 
and stroke; one time diagnosis of peripheral neuropathy; 
and one time photocoagulation procedure. Each resource 
was multiplied by its unit costs, which for medical proce-
dures, exams, hospitalization and medical visits consid-
ered SUS reimbursement values [31].
One time angina and stroke costs were obtained from 
the National Information System on Hospitalizations 
in SUS (SIH), considering costs reimbursed by SUS for 
patients admitted to SUS in 2002 with diagnosis of the 
above conditions.
Direct cost of clinical nephropathy; lower extrem-
ity amputation; and death due to stroke or CHD, were 
obtained from follow-up data from all patients with each 
of these conditions admitted at the Hospital de Clínicas 
de Porto Alegre of the Federal University of Rio Grande 
do Sul (HCPA) during 2002.
Normal medical care costs that are not specific to 
diabetes care were estimated considering the Brazilian 
Table 1 Annual transition probabilities for  health states 
considered in the model
CHD coronary heart disease
* Probability of a new case of CHD at period t given by a Weibull function
Health state Transition  
probability
Source
Normal to microalbuminuria
 Baseline 0.033 [1]
 Hypertensive with moderate control 0.056 [48]
 Hypertensive with tight control 0.038 [48]
Microalbuminuria to nephropathy
 Baseline 0.075 [2]
 Hypertensive with moderate control 0.151 [48]
 Hypertensive with tight control 0.128 [48]
Nephropathy to end-stage renal disease
 0–11 years since diabetes diagnosis 0.004 [49, 50]
 12–19 years since diabetes diagnosis 0.039 [49, 50]
 20–94 years since diabetes diagnosis 0.074 [49, 50]
Normal to peripheral neuropathy 0.0036 [1]
Peripheral neuropathy to lower-extremity amputation
 0–7 years since diabetes diagnosis 0.028 [51]
 8–12 years since diabetes diagnosis 0.046 [51]
 13–18 years since diabetes diagnosis 0.056 [51]
 19–94 years since diabetes diagnosis 0.140 [51]
Normal to photocoagulation
 Baseline 0.011 [1]
 Hypertensive with moderate control 0.017 [2]
 Hypertensive with tight control 0.010
Photocoagulation to blindness
 Baseline 0.107 [2]
 Hypertensive with moderate control 0.107 [2]
 Hypertensive with tight control 0.107 [2]
Normal to stroke Framingham  
equation
Stroke to death
 Immediate 0.142 [52]
 1 year 0.092 [52]
Normal to CHD
CHD(t) = [F(t) − F(t − 1)]/[1 − F(t − 1)]* [53]
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average government health expenditure/person (i.e., 
GNP per capita on health) of US$ 94 (Int$ 374) per year 
in 2002 [34]. Cost of death was estimated as a propor-
tion of hospital expenditures prior to death [35], obtained 
from the cohort of all patients at the HCPA who pro-
gressed to death during 2002.
Analyses
By estimating lifelong complications and death in a hypo-
thetical population cohort, the model predicts the life-
time incidence of diabetes complications and QALYs for 
each true case of diabetes, considering utility values of 
the CDC/RTI model [21–23]. Per person change in life-
years and QALY with screening were calculated, and the 
sum of all estimated costs and expected QALYs for each 
strategy considered in the analysis were used to calculate 
the incremental cost-effectiveness ratio of screening rela-
tive to no screening. All costs are presented in US dol-
lars, considering the exchange rate in December 2001 (1 
US$ =  R$ 2.35). To allow for international comparison, 
we present results in both US$ and international dol-
lars (Int$) considering year 2001/2002 purchasing power 
parity exchange rates (1 Int$ = R$ 0.59). All costs were 
converted to 2002 reais using the Consumer Price Index 
from the Brazilian Central Bank [36].
We took the perspective of the public health care sys-
tem, as the costs of the screening program were paid by 
the publicly funded SUS and the population receiving the 
benefits of the strategies evaluated is covered by the SUS. 
A baseline 5 % discount rate was applied to future costs 
and QALYs [37].
Sensitivity analysis
We conducted one way sensitivity analyses to investigate 
the effect of key parameter values and assumptions in 
cost-effectiveness ratios (Table 4).
We varied the costs of screening, intensified glycemic 
and hypertension therapy, and diabetes complications, 
as well utility weights associated with diabetes and its 
complications by ±20  %. The time assumed between 
diabetes onset and screening (detection benefit from 
screening) varied from 4 to 6 years, and discount rates 
varied from 1–10 %. Risk reduction of intensive glyce-
mic control on macrovascular complications were var-
ied to 20 % for both myocardial infarction and stroke, 
assuming that 50 % of the individuals newly diagnosed 
with diabetes would receive metformin, and consider-
ing risk reduction estimates from UKPDS 34, which 
showed a relative risk reduction of 41  % for stroke 
and 39  % for myocardial infarction [32]. We also esti-
mated how the cost-effectiveness of the BNDSP would 
change by assuming persons with diabetes would not 
receive intensive glucose and hypertension control 
under the non-screening scenario, and screening would 
occur only in hypertensive individuals only during the 
BNDSP.
Ethical considerations
This study has been carried out in accordance with 
the Declaration of Helsinki, and the study project was 
approved by the Ethics Committee of the Federal Univer-
sity of Rio Grande do Sul.
Results
Lifetime development of diabetic complications
Screening all adults aged 40 years or older decreased the 
incidence of all diabetes complications considered in the 
model and increased survival. Cumulative incidence was 
reduced from 0.49  % for non-screened population to 
0.28 % for the screened for end stage renal disease, from 
0.76 to 0.58 % for lower extremity amputation, from 8.4 
to 7.4 % for stroke, from 33.8 to 29.6 % for CHD, and from 
3.6 to 2.3  % for blindness. Screening leads to a slightly 
Table 2 Estimated prevalence of  undiagnosed diabetes, 
smoking, hypertension and  hypercholesterolemia in  the 
Brazilian population
Age group (years) Women (%) Men (%)
Prevalence of undiagnosed diabetes [28]
 40–44 1.77 2.31
 45–49 2.63 3.23
 50–54 3.56 4.30
 55–59 4.09 5.06
 60–64 4.57 4.61
 65–69 4.53 4.97
 70–74 4.62 4.75
 75 and older 4.79 4.53
Prevalence of smoking [25]
 18–34 11.8 19.2
 35–49 20.8 25.5
 50 and older 11.4 24.2
Prevalence of hypertension [26]
 35–44 17.9 15.3
 45–54 31 28.7
 55–64 47.2 37.7
 65–74 57.5 52.8
 75+ 52 46.5
Age group (years) Population (%)
Prevalence of hypercholesterolemia [27]
 Up to 24 8
 25–34 10.9
 35–44 20.9
 45–54 28.8
 55 and older 32.3
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longer life expectancy, adding approximately 13 weeks to 
the average lifespan of those detected at screening.
Diabetes‑related health care costs, life‑years and QALYs
Compared with no screening, population screening 
increases lifetime costs, primarily due to increased costs of 
introducing treatment 5 years earlier. Modeling shows that 
this cost of treatment for five additional years for those diag-
nosed was approximately 20 times the cost of screening.
Screening adults 40 years or older would increase the 
life-time costs by US$ 489 but results in a gain of 0.035 
life-years and 0.0157 QALYs (Table  5). In the base-case 
analysis, the incremental cost-effectiveness ratio was esti-
mated to be US$ 31,147 (Int$124,060) per QALY.
Sensitivity analyses
In sensitivity analyses, cost-effectiveness ratios were sen-
sitive to several parameters (Table 4), including discount 
rates, detection benefit from screening, utility rates asso-
ciated with diabetes, and cost of intensified glycemic 
control. On the other hand, varying screening cost, com-
plication costs, and intensified hypertension control had 
minimal effect.
If benefit from early glycemic control on cardiovascu-
lar outcomes was assumed, i.e., when risk reduction of 
intensive glycemic control on macrovascular complica-
tions was considered 20  % for both myocardial infarc-
tion and stroke, cost-effectiveness ratio fell to US$14,769/
QALY (Int$ 58,825/QALY). Similarly, if screening was 
conducted only among hypertensive individuals, the cost-
effectiveness ratio decreased to US$22,695/QALY (Int$ 
90,395/QALY). Assuming that non-screened individuals 
did not receive intensive glucose and hypertension con-
trols after diabetes diagnosis, incremental cost-effective-
ness ratios were considerably more favorable, estimated 
at US$ 7505/QALY gained (Int$ 29,893/QALY).
Discussion
To our knowledge, this is the first cost-effectiveness study 
based on data of an actual population-based diabetes 
screening program. Additionally, our analysis was con-
structed by incorporating data from the screening pro-
gram into an internationally recognized and validated 
model [21, 23].
Some specificities of Brazilian healthcare system should 
be considered when interpreting our results. The BNDSP 
occurred within the unique one of a national reorganiza-
tion of primary care for diabetes. In this sense, screening 
was as much a strategy used to maximize mobilization as 
an isolated objective, and therefore several less tangible 
but equally important outcomes, not considered in this 
analysis, add to its benefits. These include the training 
of primary healthcare professionals in diabetes manage-
ment, the increase in population awareness of diabetes 
as a significant health problem, the increase in access to 
healthcare services and the greater availability of drug 
therapy for individuals with diabetes and hypertension. If 
these aspects were considered, as mentioned above, the 
benefits of screening strategy would be higher.
In our base case analysis we did not consider cardio-
vascular benefit from early glycemic control for which 
evidence was not available at the time of the BNDSP; nor 
the use of statins in individuals diagnosed with diabetes 
and with high cholesterol levels, to reflect clinical prac-
tice in Brazil at the time of the BNDSP. We did, however, 
assumed that all individuals received intensified glycemic 
and hypertension treatment once diagnosed with diabe-
tes, regardless of being diagnosed through screening or 
not. Considering such assumptions, our results were not 
cost-effective by WHO’s standards, which considers the 
cost-effectiveness threshold as up to 3 times the National 
Gross Domestic Product (GDP)/capita (US$ 9150 con-
sidering the 2002 Brazilian GDP per capita of US$ 3050). 
However, this recommended threshold is proposed for 
costs per disability life years (DALYs) and not QALYs, 
and has been criticized as having major shortcomings 
[38]. As recently presented in a publication discussing CE 
thresholds, cost–effectiveness analysis is useful only in 
Table 3 Direct medical costs of  diabetes complications 
in Brazil, 2001
End-stage renal disease
CA cardiac arrest, MI myocardial infarction
Diabetes complication Type of cost Cost (2001 US$)
Nephropathy
 Clinical nephropathy One time 267
 End stage renal disease Annual 9527
Neuropathy
 Peripheral neuropathy One time 18
 Lower extremity amputation One time 309
Retinopathy
 Photocoagulation One time 15
Coronary heart disease
 Angina One time 776
Annual 669
 History of CA/MI Annual 669
 CA/MI death without hospitalization One time 15
 CA/MI death within 30 days with 
hospitalization
One time 368
 CA/MI survivors One time 776
Stroke
 Stroke One time 955
Annual 462
 Immediate death from stroke One time 180
Cost of death One time 304
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the context of the choices available in a particular setting 
and context, and resulting CE ratios should be placed in 
the context of other, local policy and programme options, 
including funding sources. Other criteria for policy 
decisions, such as equity, ethics and political feasibility, 
should be taken into account when interpreting such 
results [38].
In sensitivity analysis, changes in the effect that is 
assumed for intensive glycemic control on CHD and 
stroke risk reduction significantly affected our results, 
with cost-effectiveness ratios as low as 14,769 US$/
QALY. Though still a subject of considerable controversy, 
the current weight of the evidence suggests that glyce-
mic control aiming for the UKPDS intervention group 
target, especially with metformin a first line treatment, 
may indeed protect against CHD and stroke [32, 39, 40]. 
However, as there is still controversy on the subject, we 
opted to be conservative and not consider such impact in 
the base case.
Another important finding in our sensitivity analysis 
was that higher screening program costs impacted little 
on overall cost-effectiveness. Screening costs have been 
shown to be significantly lower in low and middle income 
countries [12]. As compared to opportunistic screening, 
additional costs of population based screening programs 
delivered as mass-population preventive health interven-
tions, such as immunization campaigns, may be justifi-
able if they reach higher participation rates and are able 
to provide additional benefits to the population.
It is important to acknowledge that the costs of drug 
therapy, medical procedures and services in Brazil are 
very low when compared to published medical care cost 
in high income countries. Evidence suggests that health 
care system reimbursement is lower than the actual costs 
of services [41]. As the costs of managing complications 
were greater than those of early intensified treatment of 
hyperglycemia and hypertension, our cost-effectiveness 
ratios may well be conservative ones.
Some limitations of our study should be acknowledged. 
First, we considered only one-time screening. Periodic, 
repeat screening would most likely yield less favorable 
cost-effectiveness ratios, as demonstrated by previous 
studies [23]. Second, the intangible benefits of the screen-
ing program mentioned above, which appear large, were 
not measured in our analyses. Last, we did not consider 
Table 4 Sensitivity analysis
Base case Incremental 
cost‑effectiveness 
ratio (US$/QALY)
Base case 31,147
Detection benefit from screening
 4 years 34,927
 6 years 27,005
Screening costs
 +20 % 31,636
 −20 % 30,708
Incremental intensified glycemic treatment costs
 +20 % 33,558
 −20 % 28,759
Incremental intensified hypertension treatment costs
 +20 % 31,083
 −20 % 31,234
Complication costs
 +20 % 30,876
 −20 % 31,442
Discount rates applied to costs and QALYs
 1 % 21,281
 10 % 44,424
Utility weights associated with diabetes
 +20 % 26,874
 −20 % 36,977
Effects of intensive glycemic control
 CHD risk reduction: 20 % 15,688
 Stroke risk reduction: 20 % 28,029
 CHD and stroke risk reduction: 20 % 14,769
Scenario Analysis
 Selective screening of screening of hypertensive 
individuals only
22,695
 Control group not receiving intensive  
glucose and hypertension treatment
7505
Table 5 Lifetime costs, life-years, QALYs and incremental cost-effectiveness per true case of diabetes diagnosed
Brazilian nationwide population screening program for diabetes, 2001
Cost (US$) (discounted) Health outcomes 
(discounted)
Incremental cost‑
effectiveness ratio
Cost of  
treatment
Cost of  
complications
Cost of  
screening
Costs of intensified  
glycemic and  
hypertension control
Total  
costs
Remaining  
QALYs
Total cost/ 
QALY (US$)
No screening 3015 911 0 344.967 4271 4.6436
Screening 3308 888 35.965 528.104 4760 4.6593
Incremental 292.378 −22.478 36.965 183.137 489 0.0157 31,147
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the use of statins in individuals diagnosed with diabetes 
and with high cholesterol levels. We opted not to because 
at the time the BNDSP was implemented, statins were 
not recommended due to their very high costs then. 
Nowadays, with lower costs of statins due to the avail-
ability of generics and their demonstrated effect in reduc-
ing macrovascular complications in diabetic individuals 
with high cholesterol levels, the recommendation of use 
of statins would result in more favorable cost-effective-
ness ratios for a screening program similar to that imple-
mented in Brazil.
A WHO expert group has recommended that coun-
tries define policies for diabetes diagnosis and treatment 
[12]. Various guidelines from high income countries 
recommend selective screening for high risk individu-
als [13–16]. Recent studies have documented that highly 
intensive glycemic control is not beneficial [42] and have 
failed to document that intensive treatment after screen-
ing [43] reduces cardiovascular events and mortality [44]. 
However, the interventions we modeled were less inten-
sive and were compared to no screening.
Recent cost-effectiveness analyses of screening aimed 
to detect not diabetes, but rather those at high risk to 
develop the disease, have suggested that, in the long 
term, such screening, followed by an intensified program 
to promote and support lifestyle changes, may be not 
only cost-effective, but also cost saving [45]. If screening 
to detect those at high risk for diabetes is implemented, 
individuals with prevalent, previously undetected dia-
betes will inevitably be identified in the process. As 
the costs of initial preventive treatment in diabetes far 
exceed those of screening, population strategies aimed 
primarily at high risk individuals could make sense [45, 
46] although a recent meta-analysis has raised the impor-
tant issue of the effectiveness of community-based inter-
ventions [47].
New studies which evaluate screening benefits and 
costs to detect both diabetes and those at high risk to 
develop diabetes are necessary to clarify the cost-effec-
tiveness of population screening strategies in today’s 
context.
Our findings are useful to any country considering 
alternatives for screening programs for the early diagno-
sis of diabetes. However, countries with different health-
care systems may find a significant difference in the 
benefits and costs of subsequent treatment of diabetes 
to prevent complications. In this regard, these results are 
generalizable only to countries with health care systems 
in which access to treatment and prevention of complica-
tions from diabetes is reasonably guaranteed.
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